Treatment of Metastatic Triple-Negative Breast Cancer
The Pharma Data
MARCH 25, 2021
SG is a first-in-class therapy targeting Trop-2, a protein frequently expressed in multiple types of epithelial tumors, such as TNBC, where high expression is associated with poor survival and relapse. More information about ASCENT is available at [link]. About Sacituzumab Govitecan-Hziy.
Let's personalize your content